March 27, 2023Open Access

Pembrolizumab mais Quimioterapia no Câncer Endometrial Avançado

Key Points

Key points are not available for this paper at this time.

Abstract

Em pacientes com câncer endometrial avançado ou recorrente, a adição de pembrolizumab à quimioterapia padrão resultou em sobrevida livre de progressão significativamente mais longa do que com quimioterapia isolada. (Financiado pelo National Cancer Institute e outros; NRG-GY018 ClinicalTrials.gov número, NCT03914612.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Ramez N. Eskander

Michael W. Sill

Lindsey Beffa

Journals

New England Journal of Medicine

Actions

Institutions

Johns Hopkins University

Cornell University

University of California, San Diego

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Pembrolizumab mais Quimioterapia no Câncer Endometrial Avançado

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider